Opendata, web and dolomites

HEXKIN

Healing Exosomes for sKIN

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEXKIN project word cloud

Explore the words cloud of the HEXKIN project. It provides you a very rough idea of what is the project "HEXKIN" about.

commercialisation    clinical    engraftment    fast    position    overcome    gap    business    ideal    treatment    cord    successful    emerged    healthcare    commercialization    accelerate    stages    capacity    validate    opportunity    considering    million    clinically    sme    accomplishment    competitive    strategies    nevertheless    diabetic    place    humans    segment    market    healing    global    skin    demand    valley    validation    models    hard    stimulation    therapeutic    suffering    reveal    burden    vascularisation    umbilical    constitute    solutions    ucb    wounds    blood    standard    improvements    cell    secreted    limited    believe    animal    restricted    70    assist    classic    generate    wound    cells    currently    trials    exogenus    safety    human    active    instrument    death    maintaining    swift    chronic    vehicle    tool    close    survival    efficacy    revenues    capital    promotion    heal    care    entrance    spin    reported    exo    severe    globally    ulcers    biocompatibility    patients    company    competition    therapies    secure   

Project "HEXKIN" data sheet

The following table provides information about the project.

Coordinator
EXOGENUS THERAPEUTICS SA 

Organization address
address: PARQUE BIOCANT NUCLEO 04 LOTE 2
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.exogenus-t.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXOGENUS THERAPEUTICS SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Currently, there are about 50 million reported cases globally of patients suffering from hard-to-close wounds, which constitute a severe cost burden to the global healthcare systems. Considering that for these patients up to 70% of the wounds may not heal with standard care, there is a high demand for new solutions with better efficacy for the treatment of wounds. Cell therapies have emerged as promising therapeutic strategies to solve the problem of chronic wounds, but the limited engraftment and survival of the cells have restricted their efficacy in late stages of human trials. Exogenus is a spin-out company dedicated to develop a new therapeutic tool for the treatment of chronic wounds – Exo-Wound - which the company now seeks to clinically validate for diabetic ulcers. Exo-Wound is based on factors secreted by Umbilical Cord Blood (UCB) cells which accelerate the healing of skin wounds through promotion of vascularisation and stimulation of skin growth. Results from the animal models reveal important improvements in the healing capacity, treatment duration and biocompatibility when compared to competition. Nevertheless, in order to secure swift product development and successful commercialisation Exogenus is in need of partnerships and capital to overcome the classic ”Valley of death” gap. We believe the SME instrument is the ideal funding vehicle for us to establish Exo-Wound clinical validation and undertake the necessary activities to demonstrate safety and efficacy of the product in humans, and eventually achieve successful, global commercialization. The project will contribute to place Exogenus in a competitive position within the advanced wound care market and assist Europe in maintaining its competitive position in the fast growing segment of active therapies. The accomplishment of the project objectives will lead to a significant business opportunity for Exogenus, and generate revenues of around €30 million, five years after market entrance.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEXKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEXKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More